5754-18-7

Usage

Chemical Properties

White powder

InChI:InChI=1/C5H6N2O2/c1-3-2-4(8)6-7-5(3)9/h2H,1H3,(H,6,8)(H,7,9)

Upstream product

• 117122-49-3 methyl-maleic acid dihydrazide 
• 616-02-4 citraconic acid anhydride 
• 64-19-7 acetic acid 
• 617-54-9 citraconic acid dimethyl ester 
• 14011-37-1 hydrazine dihydrochloride 

Downstream Products

• 19064-64-3 3,6-dichloro-4-methylpyridazine 
• 910229-66-2 5-methyl-6-oxo-1,6-dihydropyridazin-3-yl 2,4,6-triisopropylbenzenesulfonate 
• 13300-09-9 4-methyl-6-phenylpyridazin-3(2H)-one 
• 118270-06-7 6-(3-Methoxy-phenyl)-4-methyl-2H-pyridazin-3-one 
• 32193-12-7 methyl-4 (p-chloro phenyl)-6 pyridazone-3 
• 73477-02-8 (E)-4-<2-(4-methoxyphenyl)ethenyl>pyridazine 
• 1120-88-3 4-methylpyridazine 
• 89943-29-3 4-Methyl-3,6-dimethoxy-pyridazin 
• 1834-27-1 6-chloro-4-methyl-2H-pyridazin-3-one 
• 1703-07-7 6-chloro-5-methyl-2H-pyridazin-3-one 
• 717112-50-0 1,2,4-trimethyl-3,6-pyridazinedione 
• 34127-22-5 ethyl 3,6-dichloropyridazine-4-carboxylate 

Relevant academic research and scientific papers

One-step ring condensation of hydrazine derivatives and cyclic anhydrides

Hydroxypyridazinone and pyrroledione rings condensation in the reactions of hydrazine hydrate with citraconic, 2,3-dimethylmaleic, succinic and cis-cyclohexanedicarboxylic anhydrides have been conducted in the HCl aqueous solution. The pyridazine-ring condensation yields products unexpected for these conditions. They have been identified by 1H/13C NMR and X-ray diffraction. The course of the reaction toward the five- and six-membered ring condensation strongly depends on methyl and other substituents in the anhydrides and in hydrazine. The obtained products indicate that the ring condensation is controlled by the molecular strains and steric hindrances between the substituents in anhydrides and pyridazinone products. The condensation of cyclic anhydrides with hydrazines has been reduced to one-step reaction and its yield significantly increased.

PROTEIN KINASE INHIBITORS (VARIANTS), USE THEREOF IN TREATING ONCOLOGICAL DISEASES AND A PHARMACEUTICAL COMPOSITION BASED THEREON

The present invention relates to the treatment of oncological, chronic inflammatory and similar diseases with the aid of new families of chemical compounds having improved efficiency with regard to the inhibition of Abl kinase and mutant forms thereof, as well as other therapeutically significant kinases. It describes protein kinase inhibitors in the form of compounds of general formula (I) and compounds of general formula (II), or a tautomer, an individual isomer, a mixture of isomers, a pharmaceutically acceptable salt, a solvate or a hydrate thereof.

Design, synthesis, crystallographic studies, and preliminary biological appraisal of new substituted triazolo[4,3-b]pyridazin-8-amine derivatives as tankyrase inhibitors

Searching for selective tankyrases (TNKSs) inhibitors, a new small series of 6,8-disubstituted triazolo[4,3-b]piridazines has been synthesized and characterized biologically. Structure-based optimization of the starting hit compound NNL (3) prompted us to the discovery of 4-(2-(6-methyl-[1,2,4] triazolo[4,3-b]pyridazin-8-ylamino)ethyl)phenol (12), a low nanomolar selective TNKSs inhibitor working as NAD isostere as ascertained by crystallographic analysis. Preliminary biological data candidate this new class of derivatives as a powerful pharmacological tools in the unraveling of TNKS implications in physiopathological conditions.

Phosphodiesterase inhibitors. Part 3: Design, synthesis and structure-activity relationships of dual PDE3/4-inhibitory fused bicyclic heteroaromatic-dihydropyridazinones with anti-inflammatory and bronchodilatory activity

(-)-6-(7-Methoxy-2-trifluoromethylpyrazolo[1,5-a]pyridin-4-yl)-5-methyl-4, 5-dihydro-3-(2H)-pyridazinone (KCA-1490) is a dual PDE3/4 inhibitor that exhibits potent combined bronchodilatory and anti-inflammatory activity. A survey of potential bicyclic heteroaromatic replacement subunits for the pyrazolo[1,5-a]pyridine core of KCA-1490 has identified the 4-methoxy-2- (trifluoromethyl)benzo[d]thiazol-7-yl and 8-methoxy-2-(trifluoromethyl)quinolin- 5-yl analogues as dual PDE3/4-inhibitory compounds that potently suppress histamine-induced bronchoconstriction and exhibit anti-inflammatory activity in vivo.